Gene symbol |
Time course plot |
Accession |
Description |
Treatment |
15min |
30min |
1hr |
2hr |
4hr |
8hr |
20hr |
AK044510
|  |
AK044510 |
adult retina cDNA, RIKEN full-length enriched library, clone:A930017M14 product:laminin, alpha 1, full insert sequence. [AK044510] |
KLA | .96 |
1.07 |
1.03 |
1.05 |
1.00 |
1.06 |
1.16 |
| ATP | 1.04 |
1.04 |
1.04 |
1.04 |
1.05 |
1.08 |
1.01 |
| KLA/ATP | .96 |
1.08 |
1.07 |
1.10 |
1.12 |
1.08 |
1.01 |
|
Akt1 |  |
NM_009652 |
thymoma viral proto-oncogene 1 (Akt1), mRNA [NM_009652] |
KLA | .80 |
.80 |
.75 |
.75 |
.71 |
.70 |
.82 |
| ATP | 1.00 |
1.02 |
.76 |
.85 |
.76 |
.68 |
.84 |
| KLA/ATP | .82 |
.80 |
.64 |
.68 |
.67 |
.61 |
.72 |
|
Akt2 |  |
NM_007434 |
thymoma viral proto-oncogene 2 (Akt2), transcript variant 2, mRNA [NM_007434] |
KLA | 1.45 |
1.49 |
1.81 |
1.61 |
1.83 |
1.17 |
.92 |
| ATP | 1.12 |
1.12 |
1.00 |
1.28 |
1.20 |
.94 |
1.06 |
| KLA/ATP | 1.48 |
1.70 |
1.69 |
1.58 |
1.57 |
1.32 |
1.27 |
|
Akt3 |  |
NM_011785 |
thymoma viral proto-oncogene 3 (Akt3), mRNA [NM_011785] |
KLA | 3.42 |
3.45 |
5.31 |
5.16 |
4.65 |
3.80 |
2.12 |
| ATP | 1.12 |
1.22 |
1.10 |
1.37 |
1.02 |
1.11 |
1.56 |
| KLA/ATP | 3.72 |
4.17 |
4.62 |
4.64 |
2.74 |
2.05 |
3.82 |
|
Apaf1 |  |
NM_001042558 |
apoptotic peptidase activating factor 1 (Apaf1), transcript variant 1, mRNA [NM_001042558] |
KLA | 2.92 |
2.81 |
3.22 |
2.74 |
2.42 |
1.74 |
1.40 |
| ATP | 1.05 |
.99 |
.87 |
.81 |
1.61 |
2.03 |
1.46 |
| KLA/ATP | 2.90 |
2.78 |
2.01 |
1.69 |
1.56 |
2.77 |
2.73 |
|
BC010335
|  |
BC010335 |
fibronectin 1, mRNA (cDNA clone IMAGE:3156499), **** WARNING: chimeric clone ****. [BC010335] |
KLA | .94 |
.88 |
1.01 |
.99 |
.95 |
.95 |
1.07 |
| ATP | 1.06 |
.98 |
1.20 |
1.30 |
1.07 |
.97 |
.97 |
| KLA/ATP | .93 |
1.00 |
1.07 |
1.20 |
1.02 |
.96 |
.94 |
|
Bcl2 |  |
NM_009741 |
B-cell leukemia/lymphoma 2 (Bcl2), transcript variant 1, mRNA [NM_009741] |
KLA | .30 |
.26 |
.25 |
.25 |
.34 |
.38 |
.26 |
| ATP | .97 |
.89 |
1.50 |
1.04 |
.99 |
.29 |
.52 |
| KLA/ATP | .28 |
.26 |
.40 |
.33 |
.62 |
.29 |
.12 |
|
Bcl2 |  |
NM_177410 |
B-cell leukemia/lymphoma 2 (Bcl2), transcript variant 2, mRNA [NM_177410] |
KLA | .33 |
.33 |
.37 |
.42 |
.49 |
.46 |
.39 |
| ATP | 1.07 |
1.12 |
1.22 |
1.56 |
1.00 |
.38 |
.76 |
| KLA/ATP | .35 |
.34 |
.54 |
.89 |
.76 |
.36 |
.23 |
|
Bcl2l1 |  |
NM_009743 |
Bcl2-like 1 (Bcl2l1), nuclear gene encoding mitochondrial protein, mRNA [NM_009743] |
KLA | .99 |
1.02 |
1.10 |
1.16 |
1.27 |
.97 |
1.05 |
| ATP | 1.18 |
1.42 |
.81 |
1.26 |
1.51 |
.71 |
1.67 |
| KLA/ATP | 1.21 |
1.30 |
.66 |
1.15 |
1.31 |
1.17 |
1.59 |
|
Birc2 |  |
NM_007465 |
baculoviral IAP repeat-containing 2 (Birc2), mRNA [NM_007465] |
KLA | 4.63 |
4.59 |
3.77 |
2.79 |
2.32 |
2.07 |
1.84 |
| ATP | .95 |
.88 |
.84 |
.92 |
.76 |
1.34 |
1.28 |
| KLA/ATP | 4.70 |
4.93 |
4.13 |
2.60 |
1.34 |
1.60 |
2.31 |
|
Birc3 |  |
BC011338 |
baculoviral IAP repeat-containing 3, mRNA (cDNA clone MGC:18386 IMAGE:3661563), complete cds [BC011338] |
KLA | 5.48 |
5.46 |
4.94 |
4.16 |
4.91 |
3.36 |
3.74 |
| ATP | 1.05 |
1.08 |
4.21 |
4.28 |
2.59 |
2.55 |
1.57 |
| KLA/ATP | 6.78 |
8.91 |
11.01 |
4.87 |
2.28 |
2.12 |
3.66 |
|
Birc3 |  |
NM_007464 |
baculoviral IAP repeat-containing 3 (Birc3), mRNA [NM_007464] |
KLA | 17.83 |
15.88 |
13.48 |
11.14 |
11.79 |
6.90 |
6.10 |
| ATP | 1.14 |
1.16 |
1.70 |
4.07 |
5.00 |
6.33 |
2.41 |
| KLA/ATP | 14.77 |
16.44 |
19.09 |
13.91 |
8.27 |
6.22 |
7.73 |
|
Birc7 |  |
AK053463 |
0 day neonate eyeball cDNA, RIKEN full-length enriched library, clone:E130019N06 product:weakly similar to BA261N11.1.3 (BACULOVIRAL IAP REPEAT-CONTAINING PROTEIN 7 (LIVIN), ISOFORM 3) (FRAGMENT) [Homo sapiens], full insert sequence [AK05 |
KLA | 1.02 |
1.02 |
.93 |
1.01 |
.91 |
1.27 |
1.07 |
| ATP | 1.02 |
1.03 |
.99 |
.93 |
.96 |
.98 |
1.01 |
| KLA/ATP | 1.00 |
1.04 |
.97 |
.94 |
.91 |
.93 |
.92 |
|
Casp9 |  |
NM_015733 |
caspase 9 (Casp9), mRNA [NM_015733] |
KLA | .31 |
.31 |
.40 |
.66 |
.89 |
1.19 |
.91 |
| ATP | .88 |
.77 |
.91 |
.59 |
.43 |
.75 |
.93 |
| KLA/ATP | .26 |
.26 |
.30 |
.28 |
.80 |
1.06 |
.97 |
|
Ccnd1 |  |
S78355 |
gb|Cyl-1=cyclin D1 [mice, BALB/c, brain, mRNA, 3737 nt]. [S78355] |
KLA | .24 |
.23 |
.23 |
.24 |
.29 |
.47 |
.17 |
| ATP | 1.02 |
1.02 |
.88 |
.80 |
.52 |
.10 |
.21 |
| KLA/ATP | .27 |
.23 |
.22 |
.24 |
.27 |
.25 |
.14 |
|
Ccne1 |  |
NM_007633 |
cyclin E1 (Ccne1), mRNA [NM_007633] |
KLA | 1.13 |
1.14 |
1.13 |
.78 |
.51 |
.69 |
.55 |
| ATP | .92 |
.94 |
1.09 |
.93 |
.75 |
.71 |
.47 |
| KLA/ATP | 1.13 |
1.17 |
1.45 |
1.24 |
1.33 |
1.50 |
.85 |
|
Ccne2 |  |
NM_001037134 |
cyclin E2 (Ccne2), transcript variant 1, mRNA [NM_001037134] |
KLA | .34 |
.35 |
.42 |
.36 |
.35 |
.36 |
.26 |
| ATP | 1.02 |
1.11 |
1.01 |
.82 |
.58 |
.38 |
.23 |
| KLA/ATP | .36 |
.34 |
.44 |
.43 |
.41 |
.40 |
.25 |
|
Cdk2 |  |
NM_016756 |
cyclin-dependent kinase 2 (Cdk2), transcript variant 2, mRNA [NM_016756] |
KLA | .68 |
.67 |
.62 |
.63 |
.60 |
.74 |
.73 |
| ATP | 1.02 |
1.14 |
.91 |
.92 |
.68 |
.71 |
.65 |
| KLA/ATP | .67 |
.64 |
.64 |
.64 |
.61 |
.74 |
.62 |
|
Cdk4 |  |
NM_009870 |
cyclin-dependent kinase 4 (Cdk4), mRNA [NM_009870] |
KLA | .66 |
.72 |
.65 |
.55 |
.46 |
.50 |
.71 |
| ATP | 1.03 |
1.02 |
.53 |
.65 |
.66 |
.63 |
.75 |
| KLA/ATP | .78 |
.61 |
.31 |
.42 |
.44 |
.62 |
.43 |
|
Cdk6 |  |
AK030810 |
adult male thymus cDNA, RIKEN full-length enriched library, clone:5830411I20 product:unclassifiable, full insert sequence [AK030810] |
KLA | 1.05 |
.96 |
.67 |
.51 |
.48 |
.49 |
.45 |
| ATP | 1.02 |
.91 |
.78 |
.49 |
.50 |
.47 |
.44 |
| KLA/ATP | 1.01 |
.89 |
.65 |
.40 |
.36 |
.26 |
.49 |
|
Cdk6 |  |
NM_009873 |
cyclin-dependent kinase 6 (Cdk6), mRNA [NM_009873] |
KLA | 2.63 |
2.36 |
2.14 |
1.80 |
1.55 |
1.32 |
1.03 |
| ATP | 1.11 |
1.21 |
1.06 |
1.23 |
.94 |
1.30 |
2.08 |
| KLA/ATP | 2.58 |
2.69 |
2.24 |
2.25 |
1.38 |
.85 |
3.00 |
|
Cdkn1b |  |
NM_009875 |
cyclin-dependent kinase inhibitor 1B (Cdkn1b), mRNA [NM_009875] |
KLA | .81 |
.84 |
.84 |
.91 |
.93 |
.88 |
.97 |
| ATP | .99 |
1.09 |
.97 |
1.06 |
1.48 |
.94 |
.91 |
| KLA/ATP | .83 |
.91 |
1.04 |
1.36 |
1.48 |
1.06 |
1.09 |
|
Cdkn2b |  |
NM_007670 |
cyclin-dependent kinase inhibitor 2B (p15, inhibits CDK4) (Cdkn2b), mRNA [NM_007670] |
KLA | .70 |
.75 |
.94 |
1.44 |
1.66 |
.55 |
.81 |
| ATP | 1.02 |
.89 |
1.00 |
.86 |
1.33 |
3.87 |
.57 |
| KLA/ATP | .71 |
.77 |
.91 |
.94 |
.74 |
1.64 |
1.17 |
|
Chuk |  |
NM_007700 |
conserved helix-loop-helix ubiquitous kinase (Chuk), mRNA [NM_007700] |
KLA | 1.32 |
1.42 |
1.41 |
1.17 |
1.32 |
1.22 |
1.40 |
| ATP | 1.22 |
1.30 |
1.18 |
.97 |
1.02 |
1.00 |
1.37 |
| KLA/ATP | 1.56 |
1.61 |
1.21 |
1.09 |
.83 |
.84 |
1.17 |
|
Cks1b |  |
NM_016904 |
CDC28 protein kinase 1b (Cks1b), mRNA [NM_016904] |
KLA | .63 |
.61 |
.51 |
.46 |
.26 |
.18 |
.18 |
| ATP | .92 |
.90 |
1.37 |
1.39 |
1.12 |
.57 |
.11 |
| KLA/ATP | .56 |
.59 |
.71 |
.75 |
.63 |
.26 |
.06 |
|
Cks2 |  |
NM_025415 |
CDC28 protein kinase regulatory subunit 2 (Cks2), mRNA [NM_025415] |
KLA | .52 |
.50 |
.48 |
.49 |
.35 |
.27 |
.19 |
| ATP | .92 |
.98 |
1.53 |
1.98 |
2.18 |
1.57 |
.12 |
| KLA/ATP | .48 |
.49 |
.81 |
1.20 |
2.25 |
1.82 |
.29 |
|
Col4a1 |  |
NM_009931 |
collagen, type IV, alpha 1 (Col4a1), mRNA [NM_009931] |
KLA | 1.13 |
1.19 |
1.12 |
1.09 |
1.04 |
.89 |
.90 |
| ATP | 1.01 |
1.17 |
1.02 |
1.04 |
.91 |
.89 |
.97 |
| KLA/ATP | 1.14 |
1.24 |
1.03 |
1.15 |
.95 |
.86 |
1.01 |
|
Col4a2 |  |
NM_009932 |
collagen, type IV, alpha 2 (Col4a2), mRNA [NM_009932] |
KLA | 1.30 |
1.45 |
1.54 |
1.40 |
1.71 |
1.71 |
2.12 |
| ATP | 1.09 |
1.07 |
.98 |
1.03 |
.92 |
1.21 |
1.42 |
| KLA/ATP | 1.45 |
1.53 |
1.24 |
1.29 |
1.16 |
1.57 |
3.31 |
|
Col4a3 |  |
NM_007734 |
collagen, type IV, alpha 3 (Col4a3), mRNA [NM_007734] |
KLA | 1.09 |
1.11 |
1.12 |
1.10 |
1.05 |
1.06 |
1.04 |
| ATP | 1.02 |
1.03 |
1.01 |
.99 |
1.01 |
1.07 |
1.07 |
| KLA/ATP | 1.04 |
1.13 |
1.01 |
1.09 |
1.02 |
.98 |
1.01 |
|
Col4a4 |  |
NM_007735 |
collagen, type IV, alpha 4 (Col4a4), mRNA [NM_007735] |
KLA | 1.35 |
1.29 |
1.33 |
1.39 |
1.30 |
1.18 |
.98 |
| ATP | 1.14 |
1.08 |
1.30 |
1.54 |
1.54 |
1.34 |
.93 |
| KLA/ATP | 1.37 |
1.41 |
1.70 |
1.88 |
1.67 |
1.29 |
1.19 |
|
Col4a5 |  |
NM_007736 |
collagen, type IV, alpha 5 (Col4a5), mRNA [NM_007736] |
KLA | 1.00 |
.95 |
.95 |
.82 |
.72 |
.58 |
.70 |
| ATP | 1.05 |
1.18 |
.98 |
.88 |
.56 |
.53 |
.57 |
| KLA/ATP | 1.04 |
1.05 |
.83 |
.82 |
.58 |
.49 |
.61 |
|
Col4a6 |  |
NM_053185 |
collagen, type IV, alpha 6 (Col4a6), mRNA [NM_053185] |
KLA | 1.06 |
1.04 |
1.00 |
1.07 |
.94 |
.93 |
.94 |
| ATP | .97 |
.96 |
1.18 |
1.10 |
1.07 |
1.04 |
.86 |
| KLA/ATP | 1.00 |
1.05 |
1.22 |
1.06 |
1.12 |
1.02 |
.93 |
|
Cycs |  |
NM_007808 |
cytochrome c, somatic (Cycs), nuclear gene encoding mitochondrial protein, mRNA [NM_007808] |
KLA | 2.20 |
2.21 |
2.35 |
2.69 |
2.62 |
3.22 |
2.14 |
| ATP | .87 |
.89 |
1.31 |
1.05 |
1.06 |
1.20 |
1.26 |
| KLA/ATP | 1.88 |
2.04 |
2.86 |
2.26 |
2.57 |
2.45 |
2.03 |
|
Cyct |  |
NM_009989 |
cytochrome c, testis (Cyct), mRNA [NM_009989] |
KLA | .93 |
1.01 |
1.00 |
.99 |
1.02 |
1.03 |
.96 |
| ATP | 1.01 |
.91 |
1.01 |
.99 |
.98 |
.95 |
.95 |
| KLA/ATP | 1.10 |
.96 |
.89 |
.89 |
1.10 |
1.05 |
.97 |
|
E2f1 |  |
NM_007891 |
E2F transcription factor 1 (E2f1), mRNA [NM_007891] |
KLA | .41 |
.44 |
.42 |
.41 |
.48 |
.77 |
.90 |
| ATP | 1.01 |
1.09 |
1.04 |
1.13 |
.83 |
.53 |
.84 |
| KLA/ATP | .44 |
.44 |
.52 |
.50 |
.49 |
.46 |
.85 |
|
E2f2 |  |
NM_177733 |
E2F transcription factor 2 (E2f2), mRNA [NM_177733] |
KLA | .13 |
.13 |
.14 |
.20 |
.19 |
.19 |
.18 |
| ATP | 1.08 |
.92 |
1.01 |
.85 |
.65 |
.38 |
.38 |
| KLA/ATP | .13 |
.13 |
.21 |
.20 |
.32 |
.24 |
.26 |
|
E2f3 |  |
AK085296 |
0 day neonate kidney cDNA, RIKEN full-length enriched library, clone:D630007K21 product:E2F transcription factor 3, full insert sequence. [AK085296] |
KLA | .98 |
.97 |
1.02 |
1.00 |
.99 |
.99 |
.99 |
| ATP | .97 |
1.06 |
1.03 |
.98 |
1.01 |
.99 |
1.00 |
| KLA/ATP | 1.12 |
1.14 |
1.03 |
.99 |
.96 |
.93 |
.96 |
|
E2f3 |  |
NM_010093 |
E2F transcription factor 3 (E2f3), mRNA [NM_010093] |
KLA | 1.11 |
1.09 |
1.13 |
1.21 |
1.47 |
1.62 |
1.65 |
| ATP | .97 |
.98 |
1.08 |
1.15 |
1.45 |
1.73 |
1.80 |
| KLA/ATP | 1.21 |
1.13 |
1.07 |
1.20 |
1.45 |
1.56 |
1.62 |
|
Fhit |  |
NM_010210 |
fragile histidine triad gene (Fhit), mRNA [NM_010210] |
KLA | 1.16 |
1.14 |
1.22 |
1.10 |
.91 |
.82 |
.65 |
| ATP | .99 |
1.04 |
1.10 |
1.38 |
1.12 |
.81 |
.50 |
| KLA/ATP | 1.14 |
1.21 |
1.11 |
1.20 |
.96 |
.80 |
.54 |
|
Fn1 |  |
NM_010233 |
fibronectin 1 (Fn1), mRNA [NM_010233] |
KLA | 1.23 |
1.30 |
1.38 |
1.12 |
1.16 |
1.00 |
.78 |
| ATP | 1.02 |
1.19 |
1.25 |
1.56 |
1.33 |
1.05 |
.95 |
| KLA/ATP | 1.36 |
1.51 |
1.34 |
1.70 |
1.20 |
1.06 |
.93 |
|
Ikbkb |  |
NM_010546 |
inhibitor of kappaB kinase beta (Ikbkb), mRNA [NM_010546] |
KLA | 1.88 |
2.10 |
2.14 |
1.83 |
1.73 |
1.31 |
1.19 |
| ATP | .81 |
.74 |
.55 |
.49 |
.59 |
1.05 |
.96 |
| KLA/ATP | 1.86 |
1.73 |
1.39 |
1.12 |
.89 |
1.17 |
1.24 |
|
Ikbkg |  |
AK042138 |
3 days neonate thymus cDNA, RIKEN full-length enriched library, clone:A630062P04 product:unclassifiable, full insert sequence. [AK042138] |
KLA | .92 |
.87 |
.78 |
.78 |
.87 |
.88 |
.62 |
| ATP | .84 |
.71 |
.80 |
.50 |
1.15 |
2.33 |
.61 |
| KLA/ATP | .72 |
.69 |
.74 |
.48 |
1.06 |
1.97 |
.68 |
|
Ikbkg |  |
NM_010547 |
inhibitor of kappaB kinase gamma (Ikbkg), transcript variant 1, mRNA [NM_010547] |
KLA | 1.51 |
1.63 |
1.74 |
1.83 |
1.83 |
1.73 |
1.72 |
| ATP | .80 |
.79 |
.82 |
.75 |
.66 |
2.58 |
2.37 |
| KLA/ATP | 1.43 |
1.42 |
1.17 |
1.04 |
.71 |
1.54 |
3.17 |
|
Ikbkg |  |
NM_178590 |
inhibitor of kappaB kinase gamma (Ikbkg), transcript variant 2, mRNA [NM_178590] |
KLA | .84 |
.93 |
.86 |
.91 |
1.03 |
.89 |
.88 |
| ATP | 1.03 |
.98 |
.68 |
.56 |
.51 |
.93 |
.68 |
| KLA/ATP | .89 |
.81 |
.55 |
.52 |
.41 |
.67 |
.65 |
|
Itga2 |  |
NM_008396 |
integrin alpha 2 (Itga2), mRNA [NM_008396] |
KLA | 1.03 |
1.00 |
.98 |
1.01 |
.97 |
.96 |
1.00 |
| ATP | 1.05 |
.99 |
.93 |
1.02 |
1.04 |
1.03 |
.97 |
| KLA/ATP | .98 |
1.06 |
1.03 |
1.00 |
1.00 |
1.01 |
1.01 |
|
Itga2b |  |
NM_010575 |
integrin alpha 2b (Itga2b), mRNA [NM_010575] |
KLA | 1.01 |
1.00 |
.98 |
1.04 |
1.01 |
1.04 |
1.18 |
| ATP | 1.01 |
.98 |
.95 |
1.02 |
.96 |
1.13 |
1.08 |
| KLA/ATP | 1.04 |
1.02 |
1.02 |
.95 |
1.05 |
1.53 |
1.23 |
|
Itga3 |  |
NM_013565 |
integrin alpha 3 (Itga3), mRNA [NM_013565] |
KLA | 1.06 |
1.09 |
1.10 |
1.17 |
1.19 |
1.29 |
1.41 |
| ATP | .99 |
.99 |
1.05 |
1.12 |
1.20 |
1.25 |
1.33 |
| KLA/ATP | 1.08 |
1.14 |
1.15 |
1.27 |
1.28 |
1.20 |
1.39 |
|
Itga6 |  |
BC024571 |
integrin alpha 6, mRNA (cDNA clone IMAGE:5036677). [BC024571] |
KLA | .44 |
.44 |
.37 |
.28 |
.25 |
.29 |
.34 |
| ATP | .96 |
1.01 |
.90 |
.58 |
.35 |
.11 |
.22 |
| KLA/ATP | .44 |
.41 |
.34 |
.23 |
.15 |
.09 |
.08 |
|
Itga6 |  |
NM_008397 |
integrin alpha 6 (Itga6), mRNA [NM_008397] |
KLA | .57 |
.58 |
.51 |
.45 |
.43 |
.44 |
.47 |
| ATP | 1.05 |
1.12 |
.86 |
.90 |
.57 |
.27 |
.36 |
| KLA/ATP | .64 |
.67 |
.50 |
.57 |
.39 |
.29 |
.26 |
|
Itgav |  |
AK052514 |
13 days embryo lung cDNA, RIKEN full-length enriched library, clone:D430040G12 product:hypothetical protein, full insert sequence. [AK052514] |
KLA | 1.04 |
.93 |
1.05 |
1.02 |
1.01 |
.93 |
1.03 |
| ATP | 1.05 |
1.04 |
1.13 |
1.12 |
1.12 |
.91 |
1.02 |
| KLA/ATP | 1.08 |
.97 |
1.02 |
.95 |
1.01 |
.96 |
1.05 |
|
Itgav |  |
AK171739 |
activated spleen cDNA, RIKEN full-length enriched library, clone:F830008B15 product:unclassifiable, full insert sequence. [AK171739] |
KLA | 1.04 |
.97 |
1.06 |
.95 |
1.15 |
.89 |
1.11 |
| ATP | 1.41 |
1.54 |
1.64 |
2.24 |
2.74 |
1.24 |
1.18 |
| KLA/ATP | 1.09 |
1.07 |
1.03 |
1.01 |
1.72 |
1.24 |
1.10 |
|
Itgav |  |
NM_008402 |
integrin alpha V (Itgav), mRNA [NM_008402] |
KLA | 4.00 |
3.99 |
3.28 |
2.24 |
1.57 |
.95 |
1.13 |
| ATP | 1.14 |
1.22 |
1.13 |
1.39 |
2.22 |
2.47 |
1.70 |
| KLA/ATP | 4.59 |
4.61 |
2.48 |
2.44 |
1.60 |
1.88 |
2.56 |
|
Itgb1 |  |
NM_010578 |
integrin beta 1 (fibronectin receptor beta) (Itgb1), mRNA [NM_010578] |
KLA | 1.05 |
1.09 |
1.13 |
.92 |
1.01 |
.93 |
.88 |
| ATP | 1.14 |
1.30 |
.92 |
1.07 |
1.04 |
.83 |
.70 |
| KLA/ATP | 1.26 |
1.30 |
.87 |
1.02 |
.66 |
.65 |
.62 |
|
Itgb1 |  |
U37029 |
integrin beta1D mRNA, partial cds. [U37029] |
KLA | .93 |
.95 |
.96 |
1.01 |
.97 |
1.01 |
.98 |
| ATP | 1.05 |
.99 |
.99 |
1.03 |
1.03 |
.97 |
.94 |
| KLA/ATP | .99 |
.98 |
1.04 |
.97 |
1.02 |
1.01 |
.99 |
|
Lama1 |  |
NM_008480 |
laminin, alpha 1 (Lama1), mRNA [NM_008480] |
KLA | .99 |
1.04 |
.97 |
.96 |
1.01 |
.99 |
1.05 |
| ATP | 1.01 |
.99 |
.98 |
1.05 |
.99 |
1.09 |
.99 |
| KLA/ATP | 1.00 |
.97 |
.86 |
1.04 |
1.05 |
.99 |
1.00 |
|
Lama2 |  |
AK046114 |
adult male corpora quadrigemina cDNA, RIKEN full-length enriched library, clone:B230342M05 product:laminin, alpha 2, full insert sequence. [AK046114] |
KLA | 1.06 |
1.00 |
.95 |
1.10 |
1.04 |
.99 |
.96 |
| ATP | .98 |
1.09 |
1.00 |
.97 |
.96 |
1.12 |
1.01 |
| KLA/ATP | .94 |
1.04 |
1.05 |
1.00 |
.99 |
1.00 |
.98 |
|
Lama2 |  |
NM_008481 |
laminin, alpha 2 (Lama2), mRNA [NM_008481] |
KLA | .96 |
.99 |
.96 |
1.02 |
.95 |
1.00 |
.97 |
| ATP | 1.05 |
1.00 |
1.01 |
.94 |
1.01 |
1.04 |
.96 |
| KLA/ATP | .99 |
1.04 |
1.06 |
1.10 |
.98 |
.95 |
.97 |
|
Lama2 |  |
U12147 |
laminin-2 alpha2 chain mRNA, complete cds. [U12147] |
KLA | .96 |
1.00 |
.99 |
1.00 |
.98 |
1.02 |
1.03 |
| ATP | 1.01 |
.99 |
1.02 |
1.04 |
1.01 |
.99 |
1.02 |
| KLA/ATP | 1.00 |
1.01 |
1.00 |
1.01 |
.99 |
1.04 |
1.00 |
|
Lama3 |  |
XM_140451 |
gb|PREDICTED: Mus musculus laminin, alpha 3, transcript variant 1 (Lama3), mRNA [XM_140451] |
KLA | .76 |
.75 |
.73 |
.75 |
.71 |
.74 |
.67 |
| ATP | 1.04 |
1.12 |
1.05 |
1.20 |
.88 |
.73 |
.78 |
| KLA/ATP | .77 |
.81 |
.78 |
.82 |
.78 |
.71 |
.70 |
|
Lama4 |  |
NM_010681 |
laminin, alpha 4 (Lama4), mRNA [NM_010681] |
KLA | .99 |
.99 |
1.01 |
1.02 |
.98 |
.97 |
.96 |
| ATP | 1.00 |
1.08 |
1.05 |
1.05 |
1.03 |
1.04 |
.96 |
| KLA/ATP | 1.00 |
1.03 |
.93 |
1.00 |
.94 |
.90 |
.95 |
|
Lama5 |  |
NM_001081171 |
laminin, alpha 5 (Lama5), mRNA [NM_001081171] |
KLA | 1.11 |
1.07 |
1.09 |
1.00 |
.96 |
1.00 |
1.01 |
| ATP | 1.01 |
.99 |
1.03 |
1.01 |
1.00 |
.99 |
.99 |
| KLA/ATP | 1.12 |
1.08 |
1.05 |
1.04 |
.99 |
1.09 |
1.04 |
|
Lamb1-1 |  |
NM_008482 |
laminin B1 subunit 1 (Lamb1-1), mRNA [NM_008482] |
KLA | .93 |
.99 |
1.10 |
1.01 |
.95 |
1.00 |
.86 |
| ATP | .99 |
1.13 |
1.06 |
.99 |
1.07 |
.99 |
.97 |
| KLA/ATP | 1.00 |
1.06 |
.98 |
.95 |
.93 |
.89 |
1.04 |
|
Lamb2 |  |
NM_008483 |
laminin, beta 2 (Lamb2), mRNA [NM_008483] |
KLA | .93 |
.90 |
.95 |
.81 |
.79 |
.58 |
.37 |
| ATP | 1.01 |
1.09 |
.95 |
.99 |
.80 |
.81 |
.38 |
| KLA/ATP | .96 |
.87 |
1.00 |
.91 |
.72 |
.60 |
.38 |
|
Lamb3 |  |
NM_008484 |
laminin, beta 3 (Lamb3), mRNA [NM_008484] |
KLA | 1.00 |
.97 |
1.02 |
.98 |
1.00 |
1.04 |
.93 |
| ATP | 1.01 |
1.01 |
.91 |
.97 |
.89 |
1.04 |
1.03 |
| KLA/ATP | 1.00 |
.95 |
.97 |
1.00 |
.95 |
.87 |
1.02 |
|
Lamc1 |  |
J03484 |
gb|Mouse laminin B2 chain mRNA, complete cds [J03484] |
KLA | 1.14 |
1.01 |
1.04 |
.87 |
.82 |
.63 |
.75 |
| ATP | .99 |
1.09 |
1.07 |
1.14 |
1.36 |
2.38 |
.66 |
| KLA/ATP | 1.04 |
1.10 |
.95 |
1.12 |
1.30 |
1.70 |
.68 |
|
Lamc2 |  |
AF106279 |
laminin gamma2 chain mRNA, partial cds. [AF106279] |
KLA | 1.03 |
1.04 |
1.03 |
1.09 |
.97 |
.97 |
.98 |
| ATP | 1.04 |
1.04 |
1.16 |
1.48 |
1.46 |
1.29 |
1.26 |
| KLA/ATP | 1.04 |
1.00 |
1.03 |
1.06 |
.95 |
.99 |
1.08 |
|
Lamc2 |  |
NM_008485 |
laminin, gamma 2 (Lamc2), mRNA [NM_008485] |
KLA | 1.16 |
1.22 |
1.23 |
1.07 |
1.04 |
1.12 |
1.04 |
| ATP | 1.01 |
1.10 |
2.81 |
4.58 |
4.35 |
3.34 |
2.36 |
| KLA/ATP | 1.31 |
1.29 |
1.41 |
1.40 |
1.28 |
1.25 |
1.49 |
|
Lamc3 |  |
AF083372 |
laminin 12 gamma 3 chain mRNA, complete cds. [AF083372] |
KLA | .96 |
.94 |
.99 |
.96 |
.94 |
1.02 |
.88 |
| ATP | 1.06 |
1.00 |
.95 |
.98 |
.98 |
.99 |
1.02 |
| KLA/ATP | .90 |
.98 |
1.03 |
.95 |
.88 |
.97 |
.96 |
|
Lamc3 |  |
NM_011836 |
laminin gamma 3 (Lamc3), mRNA [NM_011836] |
KLA | 1.00 |
1.00 |
1.04 |
1.04 |
1.03 |
1.01 |
.97 |
| ATP | .99 |
1.06 |
1.00 |
.91 |
.98 |
.96 |
1.01 |
| KLA/ATP | .98 |
1.04 |
1.01 |
1.02 |
.96 |
.95 |
.98 |
|
Max |  |
NM_008558 |
Max protein (Max), mRNA [NM_008558] |
KLA | 3.40 |
3.25 |
4.09 |
4.53 |
3.19 |
2.71 |
1.19 |
| ATP | 1.17 |
1.09 |
1.13 |
.86 |
1.24 |
1.40 |
1.09 |
| KLA/ATP | 3.14 |
3.36 |
5.49 |
3.83 |
4.35 |
2.96 |
1.67 |
|
Mm.18787 9 |  |
149250519 |
Unknown |
KLA | .98 |
.98 |
1.02 |
1.05 |
1.01 |
1.10 |
1.02 |
| ATP | 1.03 |
1.00 |
.98 |
1.02 |
1.02 |
1.04 |
.99 |
| KLA/ATP | .99 |
1.07 |
1.04 |
1.02 |
.94 |
.97 |
.93 |
|
Mm.19309 9 |  |
46849811 |
Unknown |
KLA | 1.32 |
1.36 |
1.42 |
1.17 |
1.06 |
.90 |
.58 |
| ATP | .98 |
1.12 |
1.41 |
1.81 |
1.44 |
1.14 |
.89 |
| KLA/ATP | 1.39 |
1.55 |
1.57 |
2.02 |
1.43 |
1.12 |
.74 |
|
Mm.21312 8 |  |
141801344 |
Unknown |
KLA | .96 |
.95 |
.83 |
.77 |
.52 |
.99 |
1.32 |
| ATP | .80 |
.82 |
1.09 |
.80 |
.83 |
1.19 |
1.46 |
| KLA/ATP | .78 |
.92 |
.98 |
.62 |
.71 |
.94 |
1.41 |
|
Mm.25381 9 |  |
118130676 |
Unknown |
KLA | 1.81 |
1.88 |
1.96 |
1.62 |
1.89 |
2.44 |
1.56 |
| ATP | .92 |
.91 |
1.24 |
1.01 |
1.16 |
2.06 |
1.95 |
| KLA/ATP | 1.62 |
1.86 |
1.86 |
1.41 |
1.89 |
2.37 |
1.97 |
|
Mm.25806 5 |  |
148747407 |
Unknown |
KLA | 1.05 |
1.02 |
1.03 |
1.00 |
.99 |
1.05 |
.94 |
| ATP | .98 |
.98 |
1.03 |
1.02 |
.99 |
1.06 |
1.03 |
| KLA/ATP | 1.01 |
1.02 |
1.03 |
1.01 |
.96 |
.98 |
1.01 |
|
Mm.27304 9 |  |
119672895 |
Unknown |
KLA | .23 |
.22 |
.22 |
.22 |
.30 |
.51 |
.16 |
| ATP | 1.08 |
1.05 |
.88 |
.78 |
.47 |
.09 |
.20 |
| KLA/ATP | .28 |
.22 |
.21 |
.24 |
.26 |
.22 |
.12 |
|
Mm.30793 2 |  |
160333363 |
Unknown |
KLA | .13 |
.12 |
.14 |
.16 |
.15 |
.18 |
.15 |
| ATP | .92 |
.94 |
1.12 |
.93 |
.58 |
.29 |
.31 |
| KLA/ATP | .11 |
.11 |
.18 |
.20 |
.28 |
.20 |
.19 |
|
Mm.33565 9 |  |
160333365 |
Unknown |
KLA | 5.54 |
4.69 |
3.93 |
3.03 |
2.00 |
1.91 |
1.69 |
| ATP | .98 |
.81 |
1.01 |
.78 |
.68 |
1.71 |
1.10 |
| KLA/ATP | 5.05 |
4.44 |
5.07 |
2.38 |
1.34 |
1.88 |
2.00 |
|
Mm.35584
|  |
70909358 |
Unknown |
KLA | .22 |
.25 |
.28 |
.33 |
.40 |
.77 |
.46 |
| ATP | 1.05 |
.96 |
1.08 |
.56 |
1.10 |
.79 |
.74 |
| KLA/ATP | .23 |
.25 |
.32 |
.25 |
.90 |
1.02 |
.60 |
|
Mm.46002 4 |  |
38348245 |
Unknown |
KLA | 1.22 |
1.25 |
1.25 |
1.19 |
1.22 |
1.47 |
1.14 |
| ATP | 1.03 |
.94 |
1.01 |
1.01 |
2.67 |
2.31 |
1.37 |
| KLA/ATP | 1.35 |
1.19 |
1.27 |
1.22 |
1.99 |
1.83 |
1.45 |
|
Mm.46042 5 |  |
145699103 |
Unknown |
KLA | .97 |
1.06 |
1.00 |
1.00 |
1.04 |
1.00 |
1.06 |
| ATP | .98 |
1.03 |
.96 |
.96 |
1.00 |
1.05 |
.96 |
| KLA/ATP | .99 |
.95 |
1.04 |
.97 |
1.01 |
.98 |
.93 |
|
Myc |  |
NM_010849 |
myelocytomatosis oncogene (Myc), mRNA [NM_010849] |
KLA | .38 |
.31 |
.45 |
.45 |
.49 |
.35 |
.33 |
| ATP | 1.05 |
1.09 |
1.72 |
4.41 |
1.28 |
.45 |
.76 |
| KLA/ATP | .37 |
.30 |
.44 |
1.23 |
.34 |
.17 |
.19 |
|
Nfkb1 |  |
BC050841 |
nuclear factor of kappa light chain gene enhancer in B-cells 1, p105, mRNA (cDNA clone IMAGE:6392793), complete cds. [BC050841] |
KLA | 5.81 |
4.96 |
4.77 |
3.21 |
3.37 |
2.00 |
1.71 |
| ATP | 1.39 |
1.52 |
3.25 |
12.63 |
13.64 |
4.80 |
1.08 |
| KLA/ATP | 7.21 |
8.69 |
19.53 |
23.93 |
11.70 |
2.85 |
2.01 |
|
Nfkb1 |  |
M57999 |
gb|Mouse transcription factor NF-kappa-B DNA binding subunit mRNA, complete cds. [M57999] |
KLA | 8.55 |
7.87 |
7.35 |
6.13 |
3.51 |
1.85 |
1.38 |
| ATP | .98 |
.96 |
1.21 |
3.06 |
5.29 |
4.67 |
.69 |
| KLA/ATP | 7.32 |
7.20 |
8.71 |
10.82 |
5.55 |
2.77 |
1.54 |
|
Nfkbia |  |
NM_010907 |
nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, alpha (Nfkbia), mRNA [NM_010907] |
KLA | 18.65 |
18.46 |
13.63 |
17.88 |
14.25 |
9.17 |
7.92 |
| ATP | .91 |
1.09 |
7.11 |
32.39 |
17.44 |
10.49 |
1.72 |
| KLA/ATP | 15.57 |
17.66 |
15.73 |
23.91 |
13.83 |
10.73 |
9.48 |
|
Nos2 |  |
NM_010927 |
nitric oxide synthase 2, inducible, macrophage (Nos2), mRNA [NM_010927] |
KLA | 13.50 |
16.36 |
25.65 |
23.25 |
24.78 |
15.99 |
6.48 |
| ATP | 1.03 |
1.03 |
1.48 |
1.66 |
1.65 |
5.55 |
1.70 |
| KLA/ATP | 16.01 |
17.41 |
19.06 |
25.50 |
20.84 |
29.92 |
29.80 |
|
Pias2 |  |
NM_008602 |
protein inhibitor of activated STAT 2 (Pias2), mRNA [NM_008602] |
KLA | .85 |
.84 |
.82 |
.87 |
.80 |
1.05 |
1.03 |
| ATP | .88 |
.95 |
1.02 |
.86 |
.93 |
1.17 |
1.16 |
| KLA/ATP | .76 |
.83 |
.91 |
.77 |
.93 |
1.15 |
1.16 |
|
Pik3ca |  |
ENSMUST00000108243 |
ens|Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha isoform (EC 2.7.1.153) (PI3-kinase p110 subunit alpha) (PtdIns-3- kinase p110) (PI3K). [Source:Uniprot/SWISSPROT;Acc:P42337] [ENSMUST00000108243] |
KLA | 1.07 |
1.01 |
.91 |
.90 |
.98 |
.96 |
.86 |
| ATP | 1.03 |
.87 |
1.12 |
.63 |
1.22 |
1.86 |
.60 |
| KLA/ATP | 1.05 |
.82 |
.91 |
.61 |
1.17 |
1.26 |
.63 |
|
Pik3ca |  |
NM_008839 |
phosphatidylinositol 3-kinase, catalytic, alpha polypeptide (Pik3ca), mRNA [NM_008839] |
KLA | 1.15 |
1.11 |
1.05 |
.82 |
.99 |
1.03 |
1.27 |
| ATP | .98 |
1.00 |
.79 |
.75 |
.96 |
1.32 |
1.10 |
| KLA/ATP | 1.10 |
.98 |
.64 |
.72 |
.80 |
1.20 |
1.41 |
|
Pik3cb |  |
NM_029094 |
phosphatidylinositol 3-kinase, catalytic, beta polypeptide (Pik3cb), mRNA [NM_029094] |
KLA | 1.06 |
1.06 |
1.03 |
.73 |
.68 |
.98 |
1.69 |
| ATP | 1.04 |
1.21 |
.95 |
1.02 |
.85 |
.93 |
1.73 |
| KLA/ATP | 1.15 |
1.27 |
.73 |
.83 |
.58 |
.81 |
1.81 |
|
Pik3cd |  |
NM_008840 |
phosphatidylinositol 3-kinase catalytic delta polypeptide (Pik3cd), transcript variant 1, mRNA [NM_008840] |
KLA | 2.28 |
2.42 |
3.10 |
4.17 |
3.35 |
2.31 |
1.34 |
| ATP | 1.02 |
.91 |
.99 |
.63 |
.30 |
.67 |
.80 |
| KLA/ATP | 2.14 |
2.23 |
2.70 |
1.51 |
1.17 |
.85 |
.72 |
|
Pik3cd |  |
U86587 |
phosphatidylinositol 3-kinase catalytic subunit p110 delta mRNA, complete cds. [U86587] |
KLA | 2.21 |
2.24 |
3.71 |
3.17 |
3.67 |
2.66 |
1.48 |
| ATP | 1.00 |
1.03 |
.93 |
.96 |
.46 |
.75 |
.97 |
| KLA/ATP | 2.27 |
2.32 |
1.97 |
2.02 |
1.01 |
.99 |
.98 |
|
Pik3cg |  |
NM_020272 |
phosphoinositide-3-kinase, catalytic, gamma polypeptide (Pik3cg), mRNA [NM_020272] |
KLA | .53 |
.53 |
.61 |
.64 |
.97 |
.86 |
.79 |
| ATP | 1.01 |
1.13 |
.88 |
.89 |
.52 |
.53 |
.53 |
| KLA/ATP | .58 |
.53 |
.43 |
.60 |
.40 |
.43 |
.62 |
|
Pik3r1 |  |
NM_001077495 |
phosphatidylinositol 3-kinase, regulatory subunit, polypeptide 1 (p85 alpha) (Pik3r1), transcript variant 2, mRNA [NM_001077495] |
KLA | 1.05 |
1.07 |
1.03 |
1.00 |
1.01 |
1.20 |
.85 |
| ATP | .97 |
1.02 |
1.48 |
1.42 |
1.76 |
1.33 |
1.23 |
| KLA/ATP | 1.11 |
1.12 |
1.06 |
1.17 |
1.24 |
.99 |
1.12 |
|
Pik3r2 |  |
NM_008841 |
phosphatidylinositol 3-kinase, regulatory subunit, polypeptide 2 (p85 beta) (Pik3r2), mRNA [NM_008841] |
KLA | .50 |
.50 |
.48 |
.43 |
.46 |
.66 |
.75 |
| ATP | .78 |
.68 |
.45 |
.43 |
.28 |
.57 |
1.37 |
| KLA/ATP | .49 |
.38 |
.32 |
.33 |
.38 |
.67 |
1.10 |
|
Pik3r3 |  |
NM_181585 |
phosphatidylinositol 3 kinase, regulatory subunit, polypeptide 3 (p55) (Pik3r3), mRNA [NM_181585] |
KLA | 1.59 |
1.49 |
1.37 |
1.17 |
1.05 |
1.55 |
1.41 |
| ATP | 1.12 |
1.00 |
1.33 |
1.70 |
2.01 |
2.37 |
2.02 |
| KLA/ATP | 1.63 |
1.54 |
1.58 |
1.70 |
2.43 |
2.68 |
1.92 |
|
Pik3r5 |  |
NM_177320 |
phosphoinositide-3-kinase, regulatory subunit 5, p101 (Pik3r5), mRNA [NM_177320] |
KLA | 3.57 |
3.58 |
4.16 |
3.54 |
4.11 |
2.59 |
2.39 |
| ATP | 1.08 |
1.08 |
.93 |
1.67 |
3.11 |
1.88 |
1.34 |
| KLA/ATP | 3.91 |
3.70 |
3.30 |
3.80 |
2.70 |
2.04 |
3.00 |
|
Pten |  |
NM_008960 |
phosphatase and tensin homolog (Pten), mRNA [NM_008960] |
KLA | .79 |
.73 |
.61 |
.59 |
.56 |
.70 |
1.00 |
| ATP | 1.04 |
1.11 |
1.07 |
1.12 |
1.03 |
1.38 |
.83 |
| KLA/ATP | .75 |
.69 |
.60 |
.74 |
.93 |
1.09 |
1.24 |
|
Ptgs2 |  |
NM_011198 |
prostaglandin-endoperoxide synthase 2 (Ptgs2), mRNA [NM_011198] |
KLA | 181.04 |
220.88 |
218.58 |
132.79 |
103.05 |
22.69 |
18.02 |
| ATP | 2.47 |
9.45 |
52.13 |
208.62 |
271.22 |
306.11 |
6.86 |
| KLA/ATP | 233.39 |
387.29 |
617.86 |
###.## |
608.44 |
290.80 |
112.22 |
|
Ptk2 |  |
NM_007982 |
PTK2 protein tyrosine kinase 2 (Ptk2), mRNA [NM_007982] |
KLA | .99 |
.99 |
1.02 |
1.04 |
1.09 |
1.22 |
1.57 |
| ATP | 1.04 |
1.09 |
.95 |
.98 |
.67 |
.96 |
.87 |
| KLA/ATP | .99 |
1.03 |
.87 |
.93 |
.81 |
1.16 |
1.04 |
|
Rarb |  |
NM_011243 |
retinoic acid receptor, beta (Rarb), mRNA [NM_011243] |
KLA | 1.03 |
1.01 |
1.01 |
1.02 |
1.02 |
.98 |
1.00 |
| ATP | .99 |
1.00 |
1.02 |
1.01 |
.98 |
.98 |
.99 |
| KLA/ATP | 1.02 |
1.02 |
1.00 |
.99 |
.98 |
.98 |
.99 |
|
Rarb |  |
S92180 |
gb|Mus sp. retinoic acid receptor isoform RAR-beta 4 mRNA, partial cds. [S92180] |
KLA | 1.04 |
.97 |
.96 |
1.04 |
1.01 |
1.05 |
1.00 |
| ATP | 1.03 |
.95 |
1.10 |
.96 |
1.03 |
1.05 |
.98 |
| KLA/ATP | 1.01 |
.97 |
1.06 |
.97 |
.98 |
.93 |
1.05 |
|
Rb1 |  |
NM_009029 |
retinoblastoma 1 (Rb1), mRNA [NM_009029] |
KLA | .67 |
.60 |
.55 |
.51 |
.46 |
.75 |
.79 |
| ATP | 1.04 |
1.01 |
1.12 |
.86 |
.59 |
.43 |
.76 |
| KLA/ATP | .64 |
.59 |
.58 |
.46 |
.36 |
.30 |
.65 |
|
Rela |  |
NM_009045 |
v-rel reticuloendotheliosis viral oncogene homolog A (avian) (Rela), mRNA [NM_009045] |
KLA | 2.05 |
2.05 |
2.07 |
1.75 |
1.83 |
1.58 |
1.33 |
| ATP | 1.03 |
1.08 |
1.10 |
1.44 |
1.61 |
2.48 |
1.05 |
| KLA/ATP | 2.17 |
2.27 |
2.05 |
2.47 |
1.93 |
2.35 |
2.02 |
|
Rxra |  |
NM_011305 |
retinoid X receptor alpha (Rxra), mRNA [NM_011305] |
KLA | .53 |
.55 |
.50 |
.52 |
.54 |
.85 |
1.09 |
| ATP | .95 |
1.00 |
1.18 |
1.00 |
.82 |
1.20 |
1.65 |
| KLA/ATP | .57 |
.55 |
.58 |
.55 |
.67 |
1.07 |
1.57 |
|
Rxrb |  |
NM_011306 |
retinoid X receptor beta (Rxrb), mRNA [NM_011306] |
KLA | .71 |
.75 |
.75 |
.76 |
.83 |
.81 |
.89 |
| ATP | 1.04 |
1.13 |
.94 |
1.20 |
1.13 |
.81 |
.75 |
| KLA/ATP | .80 |
.86 |
.72 |
.85 |
.83 |
.93 |
.92 |
|
Rxrg |  |
NM_009107 |
retinoid X receptor gamma (Rxrg), mRNA [NM_009107] |
KLA | .98 |
1.07 |
1.07 |
1.00 |
1.00 |
1.00 |
1.07 |
| ATP | 1.02 |
1.03 |
1.06 |
1.06 |
1.11 |
1.01 |
.99 |
| KLA/ATP | .95 |
.97 |
1.05 |
1.05 |
1.09 |
.98 |
1.06 |
|
Skp2 |  |
AF083215 |
SCF complex protein Skp2 mRNA, complete cds. [AF083215] |
KLA | .36 |
.37 |
.34 |
.37 |
.44 |
.78 |
.60 |
| ATP | 1.05 |
1.35 |
.85 |
.66 |
.83 |
.54 |
.76 |
| KLA/ATP | .33 |
.39 |
.37 |
.37 |
.65 |
.73 |
.62 |
|
Traf1 |  |
NM_009421 |
Tnf receptor-associated factor 1 (Traf1), mRNA [NM_009421] |
KLA | 44.86 |
39.03 |
38.11 |
34.21 |
36.49 |
19.69 |
14.75 |
| ATP | 1.14 |
1.04 |
1.98 |
8.16 |
16.79 |
30.81 |
6.36 |
| KLA/ATP | 46.20 |
45.67 |
45.63 |
38.00 |
27.26 |
31.47 |
63.83 |
|
Traf2 |  |
NM_009422 |
Tnf receptor-associated factor 2 (Traf2), mRNA [NM_009422] |
KLA | 3.38 |
3.62 |
3.49 |
3.36 |
3.49 |
3.39 |
2.68 |
| ATP | .97 |
1.04 |
1.00 |
1.10 |
1.54 |
2.40 |
1.55 |
| KLA/ATP | 3.38 |
3.16 |
2.93 |
2.74 |
2.67 |
3.11 |
4.70 |
|
Traf3 |  |
NM_011632 |
Tnf receptor-associated factor 3 (Traf3), transcript variant 1, mRNA [NM_011632] |
KLA | .52 |
.49 |
.51 |
.49 |
.80 |
.98 |
1.22 |
| ATP | .93 |
.92 |
.95 |
1.13 |
2.70 |
1.80 |
1.42 |
| KLA/ATP | .56 |
.50 |
.49 |
1.07 |
2.94 |
1.92 |
1.65 |
|
Traf4 |  |
NM_009423 |
Tnf receptor associated factor 4 (Traf4), mRNA [NM_009423] |
KLA | .88 |
.85 |
.85 |
.84 |
.86 |
.88 |
.91 |
| ATP | .98 |
1.01 |
1.01 |
.96 |
1.05 |
1.29 |
.93 |
| KLA/ATP | .83 |
.86 |
.83 |
.94 |
1.01 |
1.11 |
.88 |
|
Traf5 |  |
NM_011633 |
Tnf receptor-associated factor 5 (Traf5), mRNA [NM_011633] |
KLA | 1.82 |
1.92 |
1.93 |
2.10 |
2.75 |
2.08 |
1.00 |
| ATP | 1.02 |
1.04 |
1.10 |
.78 |
3.79 |
2.22 |
1.42 |
| KLA/ATP | 1.70 |
1.89 |
1.85 |
1.64 |
5.40 |
2.10 |
1.83 |
|
Traf6 |  |
NM_009424 |
Tnf receptor-associated factor 6 (Traf6), mRNA [NM_009424] |
KLA | 1.19 |
1.28 |
1.34 |
1.20 |
1.23 |
1.23 |
1.28 |
| ATP | 1.06 |
1.12 |
.92 |
1.15 |
2.46 |
1.84 |
1.40 |
| KLA/ATP | 1.32 |
1.37 |
.89 |
1.16 |
1.45 |
1.49 |
1.46 |
|
Trp53 |  |
NM_011640 |
transformation related protein 53 (Trp53), mRNA [NM_011640] |
KLA | 1.25 |
1.37 |
1.11 |
.86 |
.72 |
.71 |
.95 |
| ATP | 1.15 |
1.32 |
.90 |
1.85 |
1.26 |
.68 |
.70 |
| KLA/ATP | 1.66 |
1.49 |
.80 |
1.76 |
.81 |
.65 |
.74 |
|
Xiap |  |
NM_009688 |
X-linked inhibitor of apoptosis (Xiap), mRNA [NM_009688] |
KLA | 1.61 |
1.63 |
1.62 |
1.52 |
1.34 |
1.27 |
1.11 |
| ATP | 1.03 |
1.01 |
.99 |
.96 |
.88 |
1.19 |
1.25 |
| KLA/ATP | 1.64 |
1.63 |
1.54 |
1.33 |
1.08 |
1.19 |
1.72 |
|